Vaccine-preventable Pediatric Acute Bacterial Meningitis in France: A Time Series Analysis of a 19-Year Prospective National Surveillance Network.

"A.R. reports personal fees from MSD outside the submitted work and nonfinancial support from Pfizer and AstraZeneca. N.O. reported receiving grants from Pfizer to his institution during the conduct of the study and travel grants from Pfizer, Sanofi, and GlaxoSmithKline outside the submitted work. E.V. reports grants from a French public health agency, during the conduct of the study, grants from Pfizer and from MSD, outside the submitted work. M.K.T. performs contract work for the Institut Pasteur funded by GSK, Pfizer and Sanofi Pasteur. M.K.T. has a patent NZ630133A Patent with GSK “Vaccines for serogroup X meningococcus” issued. F.A. reports receiving personal fees from MSD, Sanofi, and AstraZeneca outside the submitted work. R.C. reported receiving personal fees from Sanofi, Pfizer, MSD, and GSK; travel grants from Pfizer and MSD, and grants from Sanofi, Pfizer, MSD, and GSK outside the submitted work. C.L. reported receiving grants from Pfizer during the conduct of the study, personal fees from Pfizer and MSD, and nonfinancial support from Pfizer outside the submitted work. The other authors have no conflicts of interest to disclose."

"This work was supported by an unrestricted grant from Pfizer and from ACTIV."

"We performed a quasi-experimental interrupted time series analysis using a long-standing population-based prospective surveillance of pediatric ABM. This surveillance network was approved by the Créteil Hospital Ethics Committee and the French National Data Protection Commission (no. 913006). The study was registered at ClinicalTrials.gov (NCT04664569)."